Breaking therapeutic barriers in neurology
Christopher Boyer Chief Business Officer, Director
Dr Christos Papadimitriou CEO & Managing Director
Dr Christian Toouli Head of Commercial Engagement
What (and whose) problem is your company trying to solve?
Our vision is to help patients and their clinicians address neurological disease by protecting, restoring and rebuilding the brain. We are developing our RealBrain(R) micro-tissue technology as a more physiologically relevant and reproducible model of healthy and diseased brain tissues, so that the biopharmaceutical industry can utilise these models to discover and develop better drugs. We are also developing our micro-tissues as neuro-regenerative tissue therapeutics with an initial focus on developing a disease modifying therapy for Parkinson’s disease.
Dr Christos Papadimitriou
CEO & Managing Director, Tessara Therapeutics
Christos is highly skilled at identifying commercial opportunities and creating spin-out entities to commercialise new IP in the pharmaceuticals and healthcare space.
What impact is your company hoping to make on the world?
To break therapeutic barriers in neurology and realise a future in which we can protect, restore and rebuild the brain.
Do you have any opinion you want to share on the influence of ESG on Deep Tech; Open Innovation models; Corporate Innovation or future deeptech innovations that excite you?
An area of innovation that excites us is the convergence of machine learning / AI into biotechnology and medicine as an exciting new frontier that we are also focused on at Tessara. Biological systems, clinical practice, biotechnology and drug development generate vast amounts of data. The potential to harness and interpret this data has the promise to lead to significant advances in how we understand medicine and its application to maintaining health and addressing diseases.